¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Bone Morphogenetic Protein Receptors, Type II"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • sphenoid bone
    ³ªºñ»À, Á¢Çü°ñ
  • scaphoid bone
    ¼Õ¹è»À, ÁÖ»ó°ñ
  • spongy bone
    °¹¼Ø»À, ÇØ¸é°ñ
  • substitution bone
    ´ë¿ë»À
  • supernumerary bone
    °úÀ×»À, °úÀ×°ñ
  • sutural bone
    ºÀÇÕ»À
  • sesamoid bone
    Á¾ÀÚ»À
  • short bone
    ªÀº»À, ´Ü°ñ
  • simple bone cyst
    ´Ü¼ø»À³¶Á¾, °í¸³¼º°ñ³¶Á¾
  • skull bone defect
    ¸Ó¸®»À°á¼Õ, µÎ°³°ñ°á¼Õ
  • temporal bone
    °üÀÚ»À, ÃøµÎ°ñ
  • tarsal bone
    ¹ß¸ñ»À, Á·±Ù°ñ
  • vascularized bone flap
    Ç÷°ü»ÀÆÇ, Ç÷°üÈ­°ñÇÇÆÇ
  • wormian bone
    º¸¸§»À
  • woven bone
    ¹«Ãþ»À
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • trapezium bone
    Å«¸¶¸§»À
  • trapezoid bone
    ÀÛÀº¸¶¸§»À
  • triangular bone
    (¢¡triquetral bone) ¼¼¸ð»À
  • triquetral bone
    ¼¼¸ð»À
  • turbinate bone
    (¢¡nasal concha) ÄÚ¼±¹Ý
  • woven bone
    ¹«Ãþ»À
  • zygomatic bone
    ±¤´ë»À
  • cantilever bone graft
    µé¸²»ÀÀ̽Ä
  • cranial bone flap
    ¸Ó¸®»ÀÇÇÆÇ(¼ú), µÎ°³°ñÇÇÆÇ
  • periosteal bone collar
    »À¸·»À°í¸®
  • marble bone disease
    (¢¡osteopetrosis) »À´ë¸®¼®Áõ, °ñÈ­¼®Áõ
  • skull bone defect
    ¸Ó¸®»À°á¼Õ, µÎ°³°ñ°á¼Õ
  • reactive bone excrescence
    ¹ÝÀÀ»Àµ¹Ãâ
  • facial bone contouring surgery
    ¾ó±¼»ÀÀ±°û±³Á¤¼ú
  • nasal bone fracture
    ÄÚ»À°ñÀý
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • protein
    ´Ü¹é(Ó±ÛÜ), ´Ü¹éÁú(Ó±ÛÜòõ)
  • protein
    ´Ü¹é(Áú)
  • protein 3
    ´Ü¹é 3
  • protein 4.1
    ´Ü¹é 4.1
  • protein A
    ´Ü¹éÁú A (Æ÷µµ±¸±ÕÀÇ)
  • protein C
    C ´Ü¹é
  • protein score
    ´Ü¹é°¡(ËÀËÑ˧) ½ÄǰÀÇ .
  • protein sensitization
    ´Ü¹é°¨ÀÛ(¡­ÊïíÂ).
  • protein separation
    ´Ü¹éºÐ¸®
  • protein sparing effect
    ´Ü¹éÁúÀý¾àÈ¿°ú(Ó±ÛÜòõï½å³üùÍý).
  • protein synthesis
    ´Ü¹éÁúÇÕ¼º.
  • protein synthesis factor
    ´Ü¹éÇÕ¼ºÀÎÀÚ(Ó±ÛÜùêà÷ì×í­).
  • protein therapy
    ´Ü¹é(Áú)¿ä¹ý(¡­èþÛö).
  • protein,actin-binding
    ¾×ƾ-°áÇÕ(´Ü¹é)
  • protein,al
    AL(´Ü¹é)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • cryptogenic type
    ÀáÀçÇü(íÖî¤úþ).
  • crystal type
    °áÁ¤Çü
  • culture, type
    Ç¥ÁرÕÁÖ, ±âÁØÁÖ
  • cyclicodevelopmental type
    ÁÖ±âÀû ¹ßÀ°Çü(ÊÙËÑËôÌ´).
  • cyclicopropagative type
    ÁÖ±âÀû Áõ½ÄÇü(ÊÙÌ¡ËàÌ´).
  • delayed type hypersensitivity
  • delayed-type hypersensitivity
    Áö¿¬Çü °ú¹Î¹ÝÀÀ
  • demand type pacemaker
    ¼ö¿äÇü½É¹ÚÁ¶À²±â.
  • demblee type mycosis fungoides
    Àü°ÝÇü±Õ»ó½ÄÀ°Á¾
  • dementia of Alzheimers type
    ¾ËÃ÷ÇÏÀ̸ÓÇü Ä¡¸Å(~û¡ ö¸Å)
  • diagnostic type protective tube housing
    ÁøÂûÇü¹æÈ£¿ë ¿¢½º¼±°ü¿ë±â.
  • diploic type
    ÆÇ»çÀÌÇü, ÆÇ°£Çü(÷ùÊàúþ).
  • dorsolumbal type
    Èä¿äºÎ Çü(ýØé¦Ý»úþ), ¹èÃø ¿äºÎ Çü(ÛÎö°é¦Ý»úþ), ¹è¿ä Çü, Èä¿ä Çü.
  • dromedary type
    ´ÜºÀÇü.
  • dysplastic type
    ¹ßÀ°ºÎÀüü°Ý(Û¡ëÀÝÕîïô÷Ì«).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • sex steroid binding plasma protein
    ¼º(àõ)½ºÅ×·ÎÀÌµå °áÇÕ(Ì¿ùê) Ç÷Àå(úìíì) ´Ü¹éÁú(úìíìÓ±ÛÜòõ)
  • signal recognition protein
    ½ÅÈ£ÀÎÁö´Ü¹éÁú(ãáûÜìãò±Ó±ÛÜòõ)
  • simple protein
    ´Ü¼ø´Ü¹éÁú(Ó¤âíÓ±ÛÜòõ)
  • single-cell protein
    ´Ü¼¼Æ÷ ´Ü¹éÁú(Ó¤á¬øàÓ±ÛÜòõ)
  • single-strand binding protein
    ¿Ü°¡´Ú °áÇմܹéÁú(Ì¿ùêÓ±ÛÜòõ)
  • single-stranded DNA binding protein
    ¿Ü°¡´Ú DNA °áÇմܹéÁú(Ì¿ùêÓ±ÛÜòõ)
  • S-protein
    S-´Ü¹éÁú(Ó±ÛÜòõ)
  • S-100 protein
    S-100 ´Ü¹éÁú(Ó±ÛÜòõ)
  • sterol carrier protein
    ½ºÅ×·Ñ ¿î¹Ýü ´Ü¹éÁú(ê¡Úæô÷Ó±ÛÜòõ)
  • structural protein
    ±¸Á¶ ´Ü¹éÁú(ϰðãÓ±ÛÜòõ)
  • Tol G protein
    Tol G ´Ü¹éÁú(Ó±ÛÜòõ)
  • translationl inhibitory protein
    ¹ø¿ª ÀúÇØ ´Ü¹éÁú(Ûèæ»îÁúªÓ±ÛÜòõ)
  • transmembrane protein
    ¸·È¾´Ü ´Ü¹éÁú(دüôÓ¨Ó±ÛÜòõ)
  • transport protein
    ¼ö¼Û ´Ü¹éÁú(âÃáêÓ±ÛÜòõ)
  • trigger protein
    ¹æ¾Æ¼è ´Ü¹éÁú(Ó±ÛÜòõ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 15
LIRBM liver, iron, red bone marrow
LS-BMD lumbar spine bone mineral density
MBLA methylbenzyl linoleic acid; mouse-specific bone-marrow-derived lymphocyte antigen
NBI neutrophil bactericidal index; no bone injury; non-battle injury
NBM no bowel movement; normal bone marrow; normal bowel movement; nothing by mouth
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 15
BMT Bone Marrow Transplantation
BMC Bone Mineral Content
BMD Bone Mineral Density
BSP Bone Sialoprotein
BW Bone Width
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • marble bone disease
    °ñ È­¼®Áõ, ´ë¸®¼® °ñº´
    ´ß ¹éÇ÷º´ À°Á¾±º¿¡ ¼ÓÇÏ´Â º´. °ñÇü ¸²ÇÁÁ¾À̶ó°íµµ ÇÏ´Â ÀÌ º´Àº, »À°¡ ±½¾îÁö´Â °ÍÀÌ Æ¯Â¡À̸ç, ¹ß»ýÀÌ µå¹°±â ¶§¹®¿¡ °æÁ¦ÀûÀ¸·Î Å« ¶æÀº ¾ø´Ù. Ç÷±¸¿Í ÀüÇô °ü°è¾øÀÌ »À ¼¼Æ÷°¡ Áõ½ÄÇϹǷΠÇ÷±¸¿¡¼­ À¯·¡ÇÏ´Â Á¾¾çÀÌ ¾Æ´Ï¶ó, ¹éÇ÷º´°ú °°Àº ¹ÙÀÌ·¯½º¿¡ ÀÇÇØ ÀϾ´Â º´À̱⠶§¹®¿¡ ¹éÇ÷º´À¸·Î Ãë±ÞµÈ´Ù.
  • mastoid bone
    À¯¾ç °ñ
  • maxillary bone
    »ó¾Ç°ñ
  • medullary bone
    ¼öÁú°ñ
  • metabolic bone disease
    ´ë»ç¼º °ñ Áúȯ
  • metastatic bone tumor
    ÀüÀ̼º °ñ Á¾¾ç
  • nasal bone
    ºñ°ñ
    ÄàµîÀ» Çü¼ºÇÏ´Â µÎ °³ÀÇ À广Çü »À Áß Çϳª.
  • nasal process of the frontal bone
    ÀüµÎ°ñ ºñºÎ
  • nonlamellar bone
    ºñÃþÆÇ°ñ
  • nonossified bone
    ºñ¼®È­µÈ °ñ
  • onlay bone graft
    ÁßÃþ°ñ ÀÌ½ÄÆí
    ÇÇÀ̽ÄÀÚÀÇ ÇÇÁú¼º °ñ À§¿¡ µ¤´Â ÀÌ½ÄÆíÀ¸·Î¼­ÀÇ »À.
  • palate bone
    ±¸°³°ñ
    µÎ°³°ñÀÇ Çϳª·Î »ó¾Ç°ñ°ú Á¢Çü°ñ¿¡ ³¢¾î °æ±¸°³ ÈÄºÎ¿Í ºñ°­ Ãøº® Èĺθ¦ ¸¸µé¸ç Á¿ì ÇÑ ½ÖÀÌ ÀÖ´Ù.
  • periosteal bone
    °ñ¸· °ñ, °ñ¸·¼º °ñ
  • periosteal bone ring
    °ñ¸· °ñȯ
  • periosteal new bone
    °ñ¸·¼º ½Å»ý°ñ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
viral hepatitis type E Hepatitis caused by a nonenveloped, single-stranded, positive-sense RNA virus 27-34 nm in diameter, unrelated to other hepatitis; it is the principal cause of enterically transmitted, waterborne, epidemic NANB hepatitis occurring primarily in Asia and Africa.
Synonym: hepatitis E.
(05 Mar 2000)
central Recklinghausen's disease type II type 1 neurofibromatosis
central type neurofibromatosis Type I neurofibromatosis.
Incomplete neurofibromatosis, multiple neurofibromas with minimal manifestations, perhaps limited to cafe-au-lait spots; individuals with minimal lesions may have offspring with severe involvement.
Synonym: abortive neurofibromatosis.
(05 Mar 2000)
glycogen storage disease type I <disease> An autosomal recessive disease in which gene expression of glucose-6-phosphatase is absent, resulting in hypoglycaemia due to lack of glucose production.
Accumulation of glycogen in liver and kidney leads to organomegaly, particularly massive hepatomegaly. Increased concentrations of lactic acid and hyperlipidemia appear in the plasma. Clinical gout often appears in early childhood.
Inheritance: autosomal recessive.
(12 Dec 1998)
glycogen storage disease type II <disease> Glycogenosis due to alpha-1,4-glucosidase (acid maltase) deficiency. It affects muscle, heart, and other organs.
(12 Dec 1998)
glycogen storage disease type III <disease> An autosomal recessive metabolic disorder due to deficient expression of amylo-1,6-glucosidase (one part of the glycogen debranching enzyme system).
The clinical course of the disease is similar to that of glycogen storage disease type I, but milder. Massive hepatomegaly, which is present in young children, diminishes and occasionally disappears with age. Levels of glycogen with short outer branches are elevated in muscle, liver, and erythrocytes. Six subgroups have been identified, with subgroups type IIIa and type IIIb being the most prevalent.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type IV <disease> An autosomal recessive metabolic disorder due to a deficiency in expression of branching enzyme (alpha-1,4-glucan-6-alpha-glucosyltransferase), resulting in an accumulation of abnormal glycogen with long outer branches. Clinical features are muscle hypotonia and cirrhosis. Death from liver disease usually occurs before age 2.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type V <disease> Glycogenosis due to muscle phosphorylase deficiency. Characterised by painful cramps following sustained exercise.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type VI <disease> A hepatic glycogen storage disease in which there is an apparent deficiency of hepatic phosphorylase activity. However, studies have not been able to distinguish between phosphorylase deficiency and phosphorylase kinase deficiency in patients with hepatic glycogenosis.
(12 Dec 1998)
glycogen storage disease type VII <disease> An autosomal recessive muscle glycogen storage disease in which there is deficient expression of muscle phosphofructokinase activity, resulting in increased concentrations of glucose-6-phosphate and fructose-6-phosphate and low concentrations of fructose-1,6-diphosphate in muscle tissue.
Glycogen storage in muscle is increased, perhaps due to activation of glycogen synthase by accumulated glucose-6-phosphate. It has been proposed that shunting of glucose-6-phosphate and fructose-6-phosphate into the pentose phosphate pathway may result in increased synthesis of purines and pyrimidines, causing hyperuricaemia and gout.
Erythrocytes from patients may show decreased phosphofructokinase activity and 2,3-diphosphoglycerate deficiency. Exercise intolerance is present and severe congenital muscular dystrophy has been reported.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type VIII <disease> An x-linked recessive hepatic glycogen storage disease resulting from lack of expression of phosphorylase-b-kinase activity. Symptoms are relatively mild; hepatomegaly, increased liver glycogen, and decreased leukocyte phosphorylase are present. Liver shrinkage occurs in response to glucagon.
Inheritance: X-linked recessive
(12 Dec 1998)
V-type ATPase <enzyme> From eukaryotic endomembrane systems, including vacuoles, lysosomes, golgi apparatus, chromaffin granules and coated vesicles. One of three major classes of ion transport ATPase, characterised by a multi subunit structure and a lack of a phosphorylated intermediate.
Found in archaebacteria but not eubacteria, in the intracellular acidic vacuoles and in some proton pumping epithelia (e.g. Intercalated cells of kidney). A complex enzyme encoded by several genes, involved in ion translocation but does not act via phosphorylated enzyme intermediate
See: P-type ATPase.
Registry number: EC 3.6.1.-
Synonym: atpase, v-type, atpase, vacuolar, vacuolar atpase, v-atpase, vacuolar h+-atpase, vacuolar membrane h(+)-atpase, vha55 gene product, vma16 gene product
(26 Jun 1999)
Gm type <immunology> Genetically determined allotypic antigens found on IgG of some individuals.
(18 Nov 1997)
Golgi type II neuron <physiology> Nerve cells with short axons which ramify in the gray matter.
(05 Mar 2000)
Golgi type I neuron <physiology> Nerve cells whose long axons leave the gray matter of which they form a part.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 15
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 15
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 15
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 15
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 15
ÅëÇÕ°Ë»ö ¿Ï·á